… lung cancer. Studies have revealed improved objective response rates, progression-free
survival, and overall survival … subset of unselected patients with lung cancer responds to these …

… survival (PFS) with alectinib versus crizotinib in treatment-naive ALK-positive non-small-cell
lung cancer (… We report mature PFS (cut-off: 30 November 2018) and overall survival (OS) …

… Overall survival (OS) and duration of response were secondary end points. … For patients
with non‒small-cell lung cancer (NSCLC), median overall survival (OS) and 5-year survival …

… survival and may be important in the development and progression of non–small cell lung
cancer … TKIs) on progression-free survival (PFS) and overall survival (OS) in advanced NSCLC …

… classification and treatment of lung cancer. Traditionally, lung cancer had been classified
based on histology. With the evolution of technologies to sequence the cancer genome and an …

8004^ Background: Afatinib (A) is an oral, irreversible ErbB family blocker of EGFR, HER2,
ErbB3 and ErbB4 signalling. LL3 compared A with cisplatin/pemetrexed in 345 pts recruited …

Introduction Lung cancer (LC) remains a disease with poor prognosis despite recent advances
in treatments. Here, we aimed at summarizing the current scientific evidence on whether …

… of chemotherapy and radiotherapy for lung cancer is overall survival. Although reliable and
… We assessed the correlations between potential surrogate endpoints and overall survival at …

… blocker, afatinib, significantly improved progression-free survival (PFS), time-to-treatment …
lung cancer (NSCLC). Here, we present primary analysis of mature overall survival (OS) data. …

… In addition, more accurate prediction of survival would allow … and predictive factors for lung
cancer survival. By contrast, … and validate a prediction model for survival of stage III NSCLC …